Biodexa Pharmaceuticals PLC has announced notable advancements in its clinical trials, marking a significant step forward in its research and development efforts. The company revealed that its Phase 3 trial of eRapa for familial adenomatous polyposis (FAP) has successfully recruited two-thirds of its participants. Additionally, preparations are underway for a Phase 1 trial of MTX240, a promising treatment for gastrointestinal stromal tumors (GIST).

Stephen Stamp, the Chief Executive Officer of Biodexa, commented on the progress, stating, “Database lock and topline data for our registrational FAP trial around the end of next year is now tantalizingly close. Also, around the same time, we should know whether we have a viable dose for MTX240 in TKI-resistant patients. If we do, MTX240 has the potential to alter standard of care for all GIST patients.”

Background

Biodexa Pharmaceuticals Plc operates in the pharmaceutical preparations sector, focusing on the development of innovative treatments for gastrointestinal cancers. The company trades on the Nasdaq under the ticker symbol BDRX. Its recent filings include a Form 6-K on October 14, 2026, and a Form 424B3 on the same date, among others.

What the Filing Says

According to the recent filing dated November 9, 2026, Biodexa has achieved significant recruitment milestones in its clinical trials. The Phase 3 trial, branded as Serenta, has enrolled 112 out of the expected 168 participants across 29 clinical sites in the US and Europe. The company anticipates that the futility analysis for this trial could occur early in 2027, with a database lock potentially happening by the end of the same year.

For the MTX240 trial, Biodexa is preparing for a Phase 1a dose escalation study, followed by a Phase 1b dose optimization study. The company expects to start recruiting patients in South Korea by mid-2027.

Impact

The advancements in Biodexa's clinical trials may significantly affect patients with familial adenomatous polyposis and gastrointestinal stromal tumors, particularly those who have developed resistance to existing treatments. The outcomes of these trials could also influence the competitive landscape within the pharmaceutical preparations industry.

What's Next

A pre-IND meeting with the FDA is scheduled for December 10, 2026, which will be crucial for the future development of MTX240. Further updates on recruitment and trial progress are expected as the company continues its research initiatives.